Sanofi Current Ratio 2010-2023 | SNY

Current and historical current ratio for Sanofi (SNY) from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Sanofi current ratio for the three months ending December 31, 2023 was 1.27.
Sanofi Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2023-12-31 $33.19B $26.19B 1.27
2023-09-30 $0.00B 0.00
2023-06-30 $32.69B $27.00B 1.21
2023-03-31 $0.00B 0.00
2022-12-31 $35.85B $25.25B 1.42
2022-09-30 $0.00B 0.00
2022-06-30 $30.18B $23.48B 1.29
2022-03-31 $0.00B 0.00
2021-09-30 $0.00B 0.00
2021-06-30 $35.55B $23.05B 1.54
2021-03-31 $0.00B 0.00
2020-09-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $29.79B $17.47B 1.71
2017-09-30 $0.00B 0.00
2017-06-30 $29.78B $18.76B 1.59
2017-03-31 $0.00B 0.00
2016-12-31 $29.53B $18.19B 1.62
2016-09-30 $0.00B 0.00
2016-06-30 $25.23B $17.22B 1.47
2016-03-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $24.35B $18.03B 1.35
2014-06-30 $27.94B $19.48B 1.43
2013-06-30 $27.17B $17.80B 1.53
2012-06-30 $27.56B $20.66B 1.33
2012-03-31 $0.00B 0.00
2011-12-31 $29.05B $18.92B 1.54
2011-09-30 $0.00B 0.00
2011-06-30 $32.57B $23.10B 1.41
2011-03-31 $0.00B 0.00
2010-12-31 $35.96B $15.62B 2.30
2010-09-30 $0.00B 0.00
2010-06-30 $31.89B $15.40B 2.07
2010-03-31 $0.00B 0.00
2009-12-31 $33.30B $17.29B 1.93
2009-09-30 $0.00B 0.00
2009-06-30 $25.23B $14.69B 1.72
2009-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $127.391B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.090B 110.29
Novo Nordisk (NVO) Denmark $601.464B 46.22
Johnson & Johnson (JNJ) United States $369.425B 14.68
Merck (MRK) United States $332.051B 60.42
AbbVie (ABBV) United States $281.850B 14.56
AstraZeneca (AZN) United Kingdom $244.317B 21.24
Novartis AG (NVS) Switzerland $208.406B 14.78
Pfizer (PFE) United States $167.731B 20.84
Innoviva (INVA) United States $1.004B 7.05